Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
You may also be interested in...
Alcresta Infused With $10M Series B To Get First Product To Market
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
Alcresta Infused With $10M Series B To Get First Product To Market
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.